Gilead's sofosbuvir aces Japanese hep C trial; Merck KGaA rejigs top management; J&J marketing exec jumps ship;

@FiercePharma: Top-read on FiercePharmaMarketing yesterday: Eli Lilly's sales force finds CRM harmony in the cloud. Story | Follow @FiercePharma

@TracyStaton: Still best-read FiercePharma: It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight. More | Follow @TracyStaton

@EricPFierce: Hikma invested $39M in NJ plant for which FDA has now closed out a warning letter from 2012. News | Follow @EricPFierce

@CarlyHFierce: GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. Article | Follow @CarlyHFierce

> Gilead Sciences ($GILD) said a key Japanese trial of its hepatitis C drug sofosbuvir showed the drug crushed the virus in 98% of previously untreated patients. Report

> Merck KGaA shuffled top management to put its consumer health chief, Udit Batra, in charge of its Millipore division, and its allergy business CEO, Uta Kemmerick-Keil, at the helm of the consumer business. Release

> Johnson & Johnson's ($JNJ) Kim Kadlec, worldwide VP of its global marketing group, jumped ship to head up relationship management at AOL. Report

> Some Indian officials are moving ahead with a bid to issue a compulsory license on Bristol-Myers Squibb's ($BMY) cancer drug Sprycel in spite of questions about the rationale behind the move. Report

> Astellas filed for European approval for broader use of its prostate cancer drug Xtandi, in patients who haven't yet had chemo. Report

Medical Device News

@FierceMedDev: Breaking: Cardinal Health is snatching up device maker AccessClosure for $320M. Story | Follow @FierceMedDev

@MarkHFierce: Last year, my sister died, and I learned first-hand about life sciences' limits. Editor's corner | Follow @MarkHFierce

@MichaelGFierce: ICYMI: The year in nanotech drug delivery. Report | Follow @MichaelGFierce

@EmilyWFierce: The FDA approved a hand-held, portable treatment to reverse an opioid overdose. News | Follow @EmilyWFierce

> After a successful IPO, LDR looks to raise more cash. More

> Biotronik proceeds with MRI-safe ICD study in the U.S. as initial patients join in. Story

Biotech News

@FierceBiotech: Party drug turned 'miracle' cure for depression spurs hype and stubborn hope. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Celgene pays VCs $47M to up its stake in Acceleron's pipeline. More | Follow @JohnCFierce

@DamianFierce: Looking back at notes from JPM in January, Lumena said it would wait on IPO until it had more data, to drive up valuation. That was pre-Q1 boom. | Follow @DamianFierce

@EmilyMFierce: Mutations during vaccine making weakened last year's flu jab. Article via FierceVaccines | Follow @EmilyMFierce

> Lumena swings for a $75M IPO to bear down on liver diseases. Story

> Pharma giants jostle for the cancer R&D spotlight at AACR. Piece

Pharma Manufacturing News

> Apotex plant in India tagged with import ban. News

> Alexion says it will add third operation in Ireland. Story

> Merck puts big data to work to solve vaccine manufacturing concern. Article

> GSK recalls Paxil after FDA issues warning letter. News

> Hikma earns FDA closeout letter for its new Jersey plant. News

> Aurobindo gets control of 7 Actavis API plants in Europe. Brief

Vaccines News

> GlaxoSmithKline admits defeat in PhIII cancer vaccine trial. News

> Mutations during vaccine making weakened last year's flu jab. Story

> GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. Story

> CDC: Flu vaccination cuts children's risk for intensive care hospitalization. Article

> Vaccines sale figures into Baxter's breakup plans. Story

> Trump's Twitter tirade blames vaccines for autism increase. Article

And Finally... More research shows that the party drug "special K," a.k.a. ketamine, might help patients with major depressive disorder. Report